The treatment of pancreatic cancer remains a significant clinical challenge due to the limited
number of patients eligible for curative (R0) surgery, failures in the clinical development of …

Abstract Development and progression of pancreatic cancer involves general metabolic
disorder, local chronic inflammation, and multistep activation of distinct oncogenic molecular …

Background and Purpose The major obstacles to treatment of pancreatic cancer are the
highly invasive capacity and resistance to chemo-and radiotherapy. Glycogen synthase …

Pancreatic cancer is an aggressive malignancy with increasing incidence and poor
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …

Tumor cell invasion and resistance to therapy are the most intractable biological
characteristics of cancer and, therefore, the most challenging for current cancer research …

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer
death in the United States with a single-digit 5-year survival rate despite advances in …

Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine protein kinase involved in
multiple normal and pathological cell functions, including cell signalling and metabolism …

Pancreatic cancer is a highly lethal disease with a poor prognosis characterized by local
and systemic disease progression. Both radiation and chemotherapy play important roles in …

Glycogen synthase kinase 3β (GSK 3β), a multifunctional serine and threonine kinase, plays
a critical role in a variety of cellular activities, including signaling transduction, protein and …

Despite tremendous scientific effort, conventional treatment approaches have had little
impact on the course of pancreatic ductal adenocarcinoma. Therefore, urgency is needed to …